1. Hualing Medicine was established in Shanghai, China. Gather leading talents in the global high-end pharmaceutical industry, integrate global innovative technologies, rely on global superior resources, develop breakthrough technologies and products, lead innovation in the pharmaceutical industry, and promote human progress.
2. Hualing Medicine is the first company in the world to realize the clinical research and development of glucokinase activator (GKA) for blood glucose sensor, and has established the technical standard and clinical medication scheme of "restoring perception, reshaping steady state and fundamentally treating diabetes", thus achieving the breakthrough of "from 0 to 1", the first new global diabetes drug in China.
1.202 1 In the first half of the year, Hualing Pharmaceutical made a breakthrough and symbolic development in the process of promoting commercialization. In March, 20021,the company submitted the application of Dogleetin, the world's first oral new drug, for type 2 diabetes in NDA, and it was accepted by NMPA on April 23rd. At present, the company is still actively preparing for the clinical, production and R&D field verification related to the review and approval, so as to promote the world's first new drug to come out as soon as possible. In addition to cooperation with CMO, the company will also establish Hualing Pharmaceutical Company in Shanghai Lingang New District to ensure sufficient commercial supply.
2. In the research and development process of Dogleetin, Hualing Medicine first put forward the scientific concept of "repairing perception, reshaping steady state and treating diabetes from the source" in the world, and realized the clinical development of this subversive product with new mechanism, new target, new structure, new technology and new curative effect. Clinical trials show that Dogleetin aims to repair the impaired glucokinase sensor function of diabetic patients from the root cause of type 2 diabetes. Significantly improve the β -cell function of patients with type 2 diabetes and reduce insulin resistance, which is expected to effectively control the progress of type 2 diabetes and has broad therapeutic prospects in patients with diabetic nephropathy (DKD).
3. In the second half of the year, the company will carry out research on the joint application of dog blood essence and existing diabetes drugs, including the joint application of dog blood essence with daglizine, insulin and GLP- 1 respectively, and explore innovative opportunities in the fields of diabetic nephropathy, metabolic syndrome diabetes, advanced diabetes and diabetic cognitive impairment. In the future, the company will also carry out clinical research on 1 diabetic patients in the United States, and plans to further promote the research and development of Dogleetin in treating diabetes.
4. Dr. Chen Li, founder, CEO and chief scientific officer of Hualing Pharmaceutical, said: "In the first half of 200212002, Hualing Pharmaceutical made important achievements in clinical research and development and promoting the commercialization process. The function of the commercialization team of Hualing Pharmaceutical has gradually improved, and the cooperation with Bayer Pharmaceuticals has become closer, which has also strengthened Hualing's confidence in completely eradicating diabetes in the future. Hualing will continue to treat diabetes more systematically and accurately on the basis of Doglietine, combined with existing drugs with different mechanisms.